Literature DB >> 3154692

Pathophysiology of myocardial ischemia: importance of platelet-vessel wall interactions.

J R Parratt1.   

Abstract

Clinical and experimental evidence for important interactions between platelets and vascular endothelium under conditions of myocardial ischemia is briefly summarized. The clinical evidence for a role of platelets in myocardial ischemia includes studies indicating alterations in platelet behavior and the therapeutic benefit of some antiplatelet drugs. Experimental evidence suggesting the importance of platelets in ischemia includes reductions in transmyocardial platelet number under these conditions, the cyclical reductions in coronary blood flow that result from intermittent intravascular platelet aggregation, and the relationship between induced platelet aggregation and cardiac arrhythmias. Evidence strongly suggesting the importance of platelet emboli and thromboxane generation as a major cause of reperfusion-induced ventricular arrhythmias is outlined.

Entities:  

Mesh:

Year:  1988        PMID: 3154692     DOI: 10.1007/bf00054250

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  36 in total

1.  Platelets, endothelium, and vasospasm.

Authors:  P M Vanhoutte; D S Houston
Journal:  Circulation       Date:  1985-10       Impact factor: 29.690

2.  Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease.

Authors:  J W Haerem
Journal:  Atherosclerosis       Date:  1972 Mar-Apr       Impact factor: 5.162

3.  Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine.

Authors:  L Jorgensen; H C Rowsell; T Hovig; M F Glynn; J F Mustard
Journal:  Lab Invest       Date:  1967-12       Impact factor: 5.662

4.  Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal's angina.

Authors:  D Tzivoni; A Keren; H Granot; S Gottlieb; J Benhorin; S Stern
Journal:  Am Heart J       Date:  1983-02       Impact factor: 4.749

5.  Antiarrhythmic effects of the thromboxane antagonist BM 13.177.

Authors:  C L Wainwright; J R Parratt
Journal:  Eur J Pharmacol       Date:  1987-01-20       Impact factor: 4.432

6.  Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.

Authors:  C R Klimt; G L Knatterud; J Stamler; P Meier
Journal:  J Am Coll Cardiol       Date:  1986-02       Impact factor: 24.094

7.  Relation of microcirculatory thrombosis to thrombus in the proximal coronary artery: effect of aspirin, dipyridamole, and thrombolysis.

Authors:  C B Moschos; K Lahiri; M Lyons; A B Weisse; H A Oldewurtel; T J Regan
Journal:  Am Heart J       Date:  1973-07       Impact factor: 4.749

8.  Platelet depletion and infarct size in an occlusion-reperfusion model of myocardial ischemia in anesthetized dogs.

Authors:  K M Mullane; J C McGiff
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.105

9.  Platelet depletion in experimental myocardial infarction.

Authors:  S R Jolly; W A Schumacher; S L Kunkel; G D Abrams; J Liddicoat; B R Lucchesi
Journal:  Basic Res Cardiol       Date:  1985 May-Jun       Impact factor: 17.165

10.  The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia.

Authors:  C L Wainwright; J R Parratt
Journal:  Adv Myocardiol       Date:  1985
View more
  1 in total

Review 1.  Nitric oxide, platelet function, myocardial infarction and reperfusion therapies.

Authors:  David Alonso; Marek W Radomski
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.